Although toxic chemotherapies effectively treat many types of cancer, these therapies contribute to poor quality of life and, in many cases, cause detrimental side effects.
Treating patients with Angiotensin-(1-7), which inhibits cancer cell growth with little or no toxicity or side effects, is a safe and effective alternative to conventional cytotoxic medicines.
Angiotensin-(1-7) inhibits cancer cell growth with little or no toxicity or side effects. This drug acts against cancer in two distinct ways – by directly inhibiting cell growth and by restricting the blood supply to tumors through reduced blood vessel formation – without the unwanted toxicity of traditional chemotherapeutics.
Ang-(1-7) has proven anti-cancer effects in preclinical models of breast, prostate, and lung cancers and sarcomas, validating its potential for use in a wide range of clinical settings. This drug has been clinical Phase 1 and Phase 2 studies which demonstrate that it is well-tolerated and that it may be an effective therapy for certain cancers and sarcomas.
- Ang-(1-7) specifically targets proliferating cancer cells, thus minimizing side effects attributed to undesired targeting of healthy cells.
- It possesses anti-cancer effects in many cancer types, including cancers of the lung, breast, prostate and sarcomas.
- It does not produce alterations in blood pressure, heart rate or wound healing when used for the treatment of cancer in the clinic at therapeutic doses.
- Ang-(1-7) and its analogs appear to act at the MAS oncogenic receptor in a novel mechanism with demonstrated translational validation.
- Treatment of sarcomas and lung, breast, prostate and connective tissue cancers.
- May also be used to treat non-solid tumors
- A successful Phase 2 clinical trial of Ang-(1-7) for second or third line treatment of patients with metastatic or unresectable sarcomas is complete.
- Phase 1 clinical trials have been completed for the study of Ang-(1-7) in the treatment of solid tumors in human patients.
- Ang-(1-7) has demonstrated effective inhibition of cancer cell growth in vitro and tumor growth in mouse models.
- Assessment of the molecular mechanisms targeted by Ang-(1-7) to mediate its anti-cancer effects are underway.
- Inventors are developing next-generation Ang-(1-7) products and formulations, including new lead compounds with pharmacological and pharmacokinetic profiles superior to Ang-(1-7) in preclinical models.
- Information on these new analogs and findings will be provided under confidentiality agreements.
- E. Ann Tallant, PhD.
- Patricia E. Gallagher, PhD.
- Carlos M. Ferrario, MD.
Phase 1 and Pharmacokinetic Study of Angiotensin-(1-7), an Endogenous Antiangiogenic Hormone. Clin Cancer Res. 2009 Dec 1;15 (23):7398-404.
Michael Batalia, PhD, CLC
Executive Director, Commercialization